All treatments
Treatment
Visugromab RDE (recommended dose for expansion) clinical trials
2 indexed studies · 2 currently recruiting
- RecruitingPHASE2
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This study looks at new treatments for advanced liver cancer that hasn't responded to initial therapy. It combines a new medicine, visugromab, with existing treatments (nivolumab and lenvatinib) to see if this mix is more effective and safe than lenvatinib alone.
For: Unresectable or Metastatic Hepatocellular Carcinoma · Child-Pugh A Hepatocellular Carcinoma · Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 CompoundGermany · Italy - RecruitingPHASE2
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
This study is for people with advanced lung cancer that has spread. It tests new treatments using a drug called Visugromab, combined with Nivolumab and sometimes Docetaxel, to see if they can work better than existing options.
For: Metastatic Non-Squamous Non-Small Cell Lung Cancer · Adult Solid TumorUnited States · Germany · Italy